Inovio Prices $17.5M Public Offering at $1.40/Share, Raising Capital Amid Financial Concerns
INO is trading near its 52-week low of $1.17 (1.3% above the low) on elevated volume (2.1× avg).
Summary
Inovio Pharmaceuticals has announced the pricing of a public offering to raise $17.5 million through the sale of 12.5 million shares and warrants at $1.40 per share. This follows a preliminary prospectus supplement (424B5) filed earlier today for a new offering and the recent suspension of their existing At-The-Market (ATM) equity program. While the offering price of $1.40 is above the current market price of $1.185, the capital raise is highly dilutive, representing a significant portion of the company's market capitalization. This move is critical for Inovio, especially given the 'going concern' warning disclosed in its recent 10-K filing, indicating a pressing need for capital. Traders will be watching the immediate market reaction to this significant dilution and how the company plans to deploy the newly raised funds to address its financial and operational challenges.
At the time of this announcement, INO was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.9M. The 52-week trading range was $1.17 to $2.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.